These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27287182)

  • 1. Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous Vaccination.
    Wang J; Li P; Wu MX
    J Invest Dermatol; 2016 Nov; 136(11):2183-2191. PubMed ID: 27287182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.
    Wang J; Li P; Yu Y; Fu Y; Jiang H; Lu M; Sun Z; Jiang S; Lu L; Wu MX
    Science; 2020 Feb; 367(6480):. PubMed ID: 32079747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
    Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5.
    Xu L; Bao L; Li F; Lv Q; Yuan J; Xu Y; Deng W; Yao Y; Yu P; Qin C
    Immunol Invest; 2014; 43(3):224-35. PubMed ID: 24295504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
    Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
    J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.
    Junkins RD; Gallovic MD; Johnson BM; Collier MA; Watkins-Schulz R; Cheng N; David CN; McGee CE; Sempowski GD; Shterev I; McKinnon K; Bachelder EM; Ainslie KM; Ting JP
    J Control Release; 2018 Jan; 270():1-13. PubMed ID: 29170142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model.
    Vassilieva EV; Li S; Korniychuk H; Taylor DM; Wang S; Prausnitz MR; Compans RW
    Front Immunol; 2020; 11():583251. PubMed ID: 33603732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].
    Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG
    Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice.
    Nakatsukasa A; Kuruma K; Okamatsu M; Hiono T; Suzuki M; Matsuno K; Kida H; Oyamada T; Sakoda Y
    Vaccine; 2017 May; 35(21):2855-2861. PubMed ID: 28431812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
    Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
    Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice.
    Vassilieva EV; Taylor DW; Compans RW
    Front Immunol; 2019; 10():3006. PubMed ID: 31921219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal vaccination with an adjuvanted polyphosphazenes nanoparticle-based vaccine formulation stimulates protective immune responses in mice.
    Schulze K; Ebensen T; Babiuk LA; Gerdts V; Guzman CA
    Nanomedicine; 2017 Oct; 13(7):2169-2178. PubMed ID: 28579436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice.
    Shi J; Wen Z; Guo J; Zhang Y; Deng G; Shu Y; Wang D; Jiang Y; Kawaoka Y; Bu Z; Chen H
    Antiviral Res; 2012 Mar; 93(3):346-53. PubMed ID: 22281419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.